MedTrace Logo

Safety Study of CNT-01 in Patients With Idiopathic TGCV

NCT02502578 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2016-09-28

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and to examine the index of the efficacy after repeated dosing of CNT-01 in patients with idiopathic triglyceride deposit cardiomyovasculopathy.

Conditions

  • Idiopathic Triglyceride Deposit Cardiomyovasculopathy

Interventions

DRUG

CNT-01 500 mg capsule

After being informed about the study and potential risks, all patients giving written informed consent undergo screening tests to determine eligibility for study enrollment. On Day 1, patients who meet the eligibility criteria will start taking CNT-01 500mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.

Sponsors & Collaborators

  • Osaka University

    lead OTHER

Principal Investigators

  • Ken-ichi Hirano, M.D., Ph.D. · Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-06-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02502578 on ClinicalTrials.gov